Prediction and Detection of Terminal Diseases Using Internet of Medical Things: A Review

Introduction to the show: ident: AI Radio. Generated commentary on the latest Artificial Intelligence papers.

Tom: I'm Tom.

Jane: And I'm Jane, here with Lu, Meng and our in-house large language model, Lalam.

Tom: Today's paper: "Prediction and Detection of Terminal Diseases Using Internet of Medical Things".

Jane: My task is to synthesize these disparate pieces of information into a single, comprehensive, and highly detailed summary that accurately reflects the scope, methodology, challenges,

Tom: First, who's behind it and why it matters.

Paper summary: Tom: So we’ve seen the high-level overview of this paper, focusing on how AI and IoMT are used for predicting terminal diseases. Now let's look at what it actually claims about the methods they review.

Jane: They start by setting up a clear distinction between traditional Machine Learning and advanced Deep Learning techniques, showing their different strengths with different types of medical data.

Lu: On the machine learning side, they focus on essential ML algorithms like XGBoost and Random Forest, which they say are pivotal for achieving high predictive accuracy, often reported at levels exceeding ninety-eight percent for conditions such as heart disease or lung cancer <ref:2410.00034#pg2>.

Meng: So we're talking about ensemble methods too then. They emphasize Gradient Boosting and Bagging as crucial enhancements to the predictive reliability by combining multiple ML models across diverse datasets.

Lalam: Deep Learning models, on the other hand, show transformative potential because they can interpret complex patterns in high-dimensional data that traditional methods miss.

Jane: Specifically, they highlight Convolutional Neural Networks or CNNs for their excellence in extracting intricate features from imaging technologies like MRI and CT scans, which is really useful for things like liver disease prediction.

Tom: And then there are Recurrent Neural Networks or RNNs and LSTMs, which are specifically noted for their capability to analyze time-series data. This lets them monitor disease progression and detect early indicators in real-time clinical settings.

Lu: They even explore amalgamations like CNN–RNN–LSTM combinations for tasks such as Alzheimer’s disease detection, which shows they're looking at complex data structures.

Meng: I want to know how this translates to real patient monitoring. The paper talks about the integration of IoMT, and it's not just about collecting data; it’s enabling real-time monitoring and personalized healthcare solutions.

Lalam: That continuous flow of vast, heterogeneous data from various medical sensors is what makes the real-time capability possible for managing chronic conditions or detecting acute events like COPD exacerbations.

Tom: So the next part of this summary is where they show how these models are applied across specific illnesses and what kind of data they use.

Jane: They systematically explore applications across a broad spectrum of chronic and terminal illnesses, often leveraging data streams directly from IoMT devices.

Lu: In cardiovascular and renal disease, models have achieved high accuracy in predicting Heart Disease CVD and Chronic Kidney Disease CKD or End Stage Renal Disease ESRD. Bi-LSTM models combined with fuzzy systems demonstrated accuracies between ninety-eight point zero three percent and ninety-eight point nine zero percent on relevant datasets for that work <ref:2410.00034#pg2>.

Meng: For neurological disorders, the focus is heavy on dementia and Alzheimer’s, utilizing deep CNNs like ResNet variants and RNN/LSTM architectures to analyze complex patient data. Some studies reported accuracies exceeding eighty percent for conditions like COVID-nineteen and Alzheimer's using pre-trained models.

Lalam: For oncology and respiratory diseases, DL models are highly effective in image analysis for lung cancer using DCNNs like ResNet one hundred one and CNNs are employed to analyze CT images for various pandemic related conditions or general lung disease or cancer prediction <ref:2410.00034#pg2>.

Tom: They also look at multi-disease prediction, which is a critical area. Research explored combining multiple deep CNNs like VGG16, ResNet, and DenseNet with XGBoost and hyperparameter optimization to enhance performance across several conditions simultaneously.

Jane: And for specific cancer prediction, they detail a sophisticated Computer Aided Detection or CAD model involving pancreas segmentation via SLIC on CT images, followed by DT-PCA feature selection and a hybrid classifier called HFB-SVM-RF, achieving ninety-six point four seven percent accuracy for that specific task <ref:2410.00034#pg2>.

Conclusion: Tom: So we’ve covered the core methods and seen the breadth of applications discussed in this review of "Prediction and Detection of Terminal Diseases Using Internet of Medical Things". Now we need to talk about what all this means in a broader sense.

Jane: The authors, Akeem Temitope Otapo, Alice Othmani, Ghazaleh Khodabandelou, and Zuheng Ming, put this together as an overview of the background of prediction and detection of chronic and terminal diseases.

Lu: They conclude by offering an extensive study and analysis of ML-, DL-, and IoMT based models used for this prediction task globally.

Meng: The implication is that while the technology is getting very good, we still have some real roadblocks before this stuff moves into standard clinical practice.

Lalam: They identify several critical challenges that impede the seamless transition of these AI/IoMT solutions from controlled environments to real-world clinical practice.

Tom: What are those hurdles? What are the biggest problems they flag for the future?

Jane: The big roadblocks include data management and integration hurdles because of the diversity in data quality and sources coming from different hospitals, research initiatives, and various IoMT devices.

Lu: They also point out model generalizability, or overfitting, is a persistent issue where models trained on specific datasets often fail to generalize when faced with new data in diverse clinical environments.

Meng: And there’s the complexity of multi-morbidity scenarios they struggle to accurately predict and diagnose conditions that occur concurrently or interact, especially involving rare or critical diseases like the intersection of dementia, stroke, and various cancers.

Lalam: Finally, there are the privacy and security imperatives because continuous IoMT data collection demands uniform data privacy standards across disparate devices to maintain integrity.

Tom: So for someone just listening to this show today what this paper means is that the technology is showing high performance numbers, but getting ready for the real world where they have to deal with messy, diverse medical data and serious security risks.

Jane: Exactly. It shows us where the research needs to go next: focusing on multi-disease models, improving data interoperability through better harmonization protocols, and making these complex models more transparent for doctors.